Dr. Miklos on Alternative Options to KTE-X19 in MCL, While Awaiting FDA Decision

Video

David Miklos, MD, discusses alternative options to the investigational CAR T-cell therapy KTE-X19 for patients with relapsed/refractory mantle cell lymphoma, while awaiting a regulatory decision from the FDA.

David Miklos, MD, associate professor of medicine, Blood and Marrow Transplantation, and clinical director of Cancer Cell Therapy at Stanford University Medical Center, discusses alternative options to the investigational CAR T-cell therapy KTE-X19 for patients with relapsed/refractory mantle cell lymphoma (MCL), while awaiting a regulatory decision from the FDA.

In February 2020, the FDA granted a priority review designation to a biologics license application (BLA) for KTE-X19 as a treatment in adult patients with relapsed/refractory MCL based on data from the phase 2 ZUMA-2 trial.

While awaiting the FDA’s decision regarding indication, price, etc., an expanded access trial is open at the same centers that in which the ZUMA-2 trial was conducted. Patients can be referred to those centers at this time and they will then be treated on a trial with close data acquisition for both clinical and adverse event collection, says Miklos. While awaiting the FDA’s decision, there is a bridge to help patients who are intolerant or refractory to BTK inhibition. Very few options are currently available to this patient population, concludes Miklos.

Related Videos
David Suhy, PhD, the cofounder and chief scientific officer of Earli
Deepak L. Bhatt, MD, MPH, MBA, on Incorporating AI into Genetic Research for Cardiovascular Disease
Jeffrey Chamberlain, PhD, on Helping Progress Cell and Gene Therapy Development
Jonathan W. Weinsaft, MD, on Integrating Genetic Research into Cardiovascular Medicine
Jacques Galipeau, MD, on Highlights from ISCT 2024’s Presidential Plenary
Vanee Pho, PhD, the senior director of product management, cell and gene therapy, at Mission Bio
Michael Wang, MD, a professor in the Department of Lymphoma/Myeloma at MD Anderson Cancer Center
Robert J. Hopkin, MD, on Looking Deeper into Fabry Disease Biology
Steven W. Pipe, MD, on Confirming Efficacy, Safety of Hemgenix Gene Therapy in Hemophilia B Populations
Rawan Faramand, MD, an assistant professor at Moffit Cancer Center
© 2024 MJH Life Sciences

All rights reserved.